ES2090714T3 - Matriz de vidrio de carbohidrato para la liberacion prolongada de un agente terapeutico. - Google Patents

Matriz de vidrio de carbohidrato para la liberacion prolongada de un agente terapeutico.

Info

Publication number
ES2090714T3
ES2090714T3 ES92925051T ES92925051T ES2090714T3 ES 2090714 T3 ES2090714 T3 ES 2090714T3 ES 92925051 T ES92925051 T ES 92925051T ES 92925051 T ES92925051 T ES 92925051T ES 2090714 T3 ES2090714 T3 ES 2090714T3
Authority
ES
Spain
Prior art keywords
therapeutic agent
carbohydrate
biologically active
glass matrix
matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92925051T
Other languages
English (en)
Inventor
Siva N Raman
John P Cunningham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Veterinary Inc
Original Assignee
Mallinckrodt Veterinary Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25184119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2090714(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mallinckrodt Veterinary Inc filed Critical Mallinckrodt Veterinary Inc
Application granted granted Critical
Publication of ES2090714T3 publication Critical patent/ES2090714T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

UNA COMPOSICION PARA LA LIBERACION ININTERRUMPIDA DE UN AGENTE TERAPEUTICO ACTIVO BIOLOGICAMENTE EN DONDE LA MATRIZ DE LA COMPOSICION DE LIBERACION ININTERRUMPIDA SE COMPONE DE UNA MATRIZ DE VIDRIO DE CARBOHIDRATO AMORFO QUE CONSTA DE UN CARBOHIDRATO ADECUADO Y UN AGENTE QUE RETARDA LA RECRISTALIZACION DEL CARBOHIDRATO Y UN AGENTE TERAPEUTICO ACTIVO BIOLOGICAMENTE Y UNA CERA INSOLUBLE EN AGUA DISPERSADA A TRAVES DE LA MATRIZ. AGENTES TERAPEUTICOS ACTIVOS BIOLOGICAMENTE QUE PUEDEN SER INCORPORADOS DENTRO DE LA MATRIZ DE VIDRIO DE CARBOHIDRATO INCLUYEN PROLACTIN, HORMONAS DE CRECIMIENTO, ALBUMINAS SERUM, FACTORES DE CRECIMIENTO Y FRAGMENTOS ACTIVOS BIOLOGICAMENTE O FORMA RECOMBINANTE DEL MISMO.
ES92925051T 1991-12-05 1992-11-02 Matriz de vidrio de carbohidrato para la liberacion prolongada de un agente terapeutico. Expired - Lifetime ES2090714T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80258191A 1991-12-05 1991-12-05

Publications (1)

Publication Number Publication Date
ES2090714T3 true ES2090714T3 (es) 1996-10-16

Family

ID=25184119

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92925051T Expired - Lifetime ES2090714T3 (es) 1991-12-05 1992-11-02 Matriz de vidrio de carbohidrato para la liberacion prolongada de un agente terapeutico.

Country Status (11)

Country Link
US (1) US5356635A (es)
EP (1) EP0615438B1 (es)
CN (1) CN1065439C (es)
AT (1) ATE140620T1 (es)
AU (1) AU3125193A (es)
CA (1) CA2125148C (es)
DE (1) DE69212497T2 (es)
DK (1) DK0615438T3 (es)
ES (1) ES2090714T3 (es)
TW (1) TW337488B (es)
WO (1) WO1993010758A1 (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE264096T1 (de) 1994-03-07 2004-04-15 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
US5817327A (en) * 1994-07-27 1998-10-06 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
DE69531992T2 (de) 1994-08-04 2004-07-22 Elan Drug Delivery Ltd., Ruddington Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
EP0782398A1 (en) 1994-09-22 1997-07-09 Quadrant Holdings Cambridge Limited Compositions for use in rehydration and nutrition during athletic exercise and methods of making same
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
ATE239451T1 (de) * 1995-06-07 2003-05-15 Elan Drug Delivery Ltd Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen
US6964771B1 (en) 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5958455A (en) * 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
DK1014941T3 (da) 1996-06-26 2009-07-27 Univ Texas Ekstruderbar farmaceutisk hot-melt-formulering
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6149939A (en) * 1997-05-09 2000-11-21 Strumor; Mathew A. Healthful dissolvable oral tablets, and mini-bars
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6352722B1 (en) 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
AU2484399A (en) * 1998-01-30 1999-08-16 Scios Inc. Controlled release delivery of peptide or protein
KR19990071255A (ko) * 1998-02-28 1999-09-15 성재갑 소마토트로핀과 비타민의 합제 조성물
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
WO2000062759A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Dry, mouldable drug formulation
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6207193B1 (en) * 1999-12-27 2001-03-27 Stephen E. Feldman Transdermal drug delivery system
KR20080011353A (ko) 2000-02-24 2008-02-01 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
MXPA03000073A (es) * 2000-06-26 2003-09-25 Monsanto Technology Llc Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.
US6664234B1 (en) * 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
DE60127139T2 (de) * 2000-07-14 2007-12-13 Novo Nordisk A/S Verfahren zum formen einer pharmazeutischen zusammensetzung in einem verpackungsmaterial
GB0124710D0 (en) * 2001-10-15 2001-12-05 Quadrant Healthcare Uk Ltd Therapeutic composition
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
EP2959893A1 (en) 2002-12-13 2015-12-30 DURECT Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006078320A2 (en) 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
PL1809329T3 (pl) 2004-09-17 2012-08-31 Durect Corp Kompozycja znieczulająca zawierająca saib o przedłużonym uwalnianiu do stosowania miejscowego
US8691772B2 (en) 2005-01-04 2014-04-08 Yeda Research And Development Co. Ltd. HSP60, HSP60 peptides and T cell vaccines for immunomodulation
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1874334A4 (en) * 2005-04-15 2011-03-30 Vascular Biogenics Ltd COMPOSITIONS WITH BETA 2-GLYCOPROTEIN I-PEPTIDES FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
JP2009501200A (ja) * 2005-07-12 2009-01-15 レノボ・リミテッド ＴＧＦ−βスーパーファミリーメンバーを含有する医薬組成物
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
GB2430880A (en) * 2005-10-04 2007-04-11 Cambridge Biostability Ltd Pharmaceutical compositions stabilized in glassy particles
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
WO2009088414A2 (en) 2007-12-06 2009-07-16 Durect Corporation Oral pharmaceutical dosage forms
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
WO2009111649A2 (en) * 2008-03-05 2009-09-11 Regenerative Research Foundation Methods and compositions for delivery of exogenous factors to nervous system sites
LT2273983T (lt) 2008-05-09 2016-10-25 Grünenthal GmbH Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
AU2010275754B2 (en) 2009-07-22 2014-05-15 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opioids
EP2456427B1 (en) 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
EP2588594B1 (en) 2010-07-01 2022-11-30 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
LT2736497T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AU2013248351B2 (en) 2012-04-18 2018-04-26 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
US11065201B2 (en) * 2014-11-21 2021-07-20 Technical University Of Denmark Gel formulations for local drug release
AU2016251854A1 (en) 2015-04-24 2017-10-19 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US10758567B2 (en) * 2015-09-16 2020-09-01 Immune Ventures LLC In vivo priming of natural killer cells
CN109475491B (zh) * 2016-05-20 2022-06-24 丹麦技术大学 可触诊的标记物组合物
EP3630201A1 (en) * 2017-05-24 2020-04-08 Technical University of Denmark Development of injectable fiducial markers for image guided radiotherapy with dual mri and ct visibility
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2413419A (en) * 1943-02-27 1946-12-31 Searle & Co Pellet for administering gonadotropic pituitary hormones
US2918411A (en) * 1957-11-01 1959-12-22 Olin Mathieson Pharmaceutical preparations
FR2383659A1 (fr) * 1977-03-16 1978-10-13 Berri Balzac Procede de preparation de comprimes contenant des substances labiles en microdispersion
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4765980A (en) * 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
US4857506A (en) * 1987-01-12 1989-08-15 American Cyanamid Company Sustained release growth hormone compositions for parenteral administration and their use
AU617417B2 (en) * 1987-11-16 1991-11-28 Baxter International Inc. Glassy matrix for administration of beneficial agent
DE68906461T2 (de) * 1988-06-07 1993-10-21 Abbott Lab Feste Arzneidosis in Form eines Tablettentriturats sowie Verfahren zu deren Herstellung.
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins

Also Published As

Publication number Publication date
AU3125193A (en) 1993-06-28
TW337488B (en) 1998-08-01
WO1993010758A1 (en) 1993-06-10
DE69212497D1 (de) 1996-08-29
CA2125148C (en) 1999-05-11
US5356635A (en) 1994-10-18
EP0615438B1 (en) 1996-07-24
CN1072861A (zh) 1993-06-09
DK0615438T3 (da) 1996-11-11
DE69212497T2 (de) 1996-12-12
CN1065439C (zh) 2001-05-09
ATE140620T1 (de) 1996-08-15
EP0615438A1 (en) 1994-09-21
CA2125148A1 (en) 1993-06-10

Similar Documents

Publication Publication Date Title
ES2090714T3 (es) Matriz de vidrio de carbohidrato para la liberacion prolongada de un agente terapeutico.
US4767628B1 (es)
DE69230475D1 (de) Verzögerte Freigabe Matrix für Arzneimittel
DK0674506T3 (da) Væksthormonholdige mikrosfærer med styret frigivelse
AU3065989A (en) Polypeptide compounds having growth hormone releasing activity
PT781550E (pt) Composicao farmaceutica bioadesiva para a libertacao controlada de principios activos
ATE68686T1 (de) System zum freigeben von stoffen in der vagina.
FI871378A0 (fi) Menetelmä valmistaa farmaseuttiseen käyttöön tarkoitettu muotokappale pelleteistä
DE69627706D1 (de) Wässrige zusammensetzung mit verzögerter freisetzung, enthaltend rinderwachstumshormon-freisetzungsfaktor
DE69513635D1 (de) Wässrige zubereitung mit verzögerter wirkstofffreigabe
IE880057L (en) Sustained release growth hormone compositions for parenteral¹administration and their use

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 615438

Country of ref document: ES

FG2A Definitive protection

Ref document number: 615438

Country of ref document: ES